39 research outputs found
Highly sensitive flow cytometry allows monitoring of changes in circulating immune cells in blood after Tdap booster vaccination
Antigen-specific serum immunoglobulin (Ag-specific Ig) levels are broadly used as correlates of protection. However, in several disease and vaccination models these fail to predict immunity. In these models, in-depth knowledge of cellular processes associated with protective versus poor responses may bring added value. We applied high-throughput multicolor flow cytometry to track over-time changes in circulating immune cells in 10 individuals following pertussis booster vaccination (Tdap, Boostrix(R), GlaxoSmithKline). Next, we applied correlation network analysis to extensively investigate how changes in individual cell populations correlate with each other and with Ag-specific Ig levels. We further determined the most informative cell subsets and analysis time points for future studies. Expansion and maturation of total IgG1 plasma cells, which peaked at day 7 post-vaccination, was the most prominent cellular change. Although these cells preceded the increase in Ag-specific serum Ig levels, they did not correlate with the increase of Ig levels. In contrast, strong correlation was observed between Ag-specific IgGs and maximum expansion of total IgG1 and IgA1 memory B cells at days 7 to 28. Changes in circulating T cells were limited, implying the need for a more sensitive approach. Early changes in innate immune cells, i.e. expansion of neutrophils, and expansion and maturation of monocytes up to day 5, most likely reflected their responses to local damage and adjuvant. Here we show that simultaneous monitoring of multiple circulating immune subsets in blood by flow cytometry is feasible. B cells seem to be the best candidates for vaccine monitoring.Immunobiology of allogeneic stem cell transplantation and immunotherapy of hematological disease
Development of a standardized and validated flow cytometry approach for monitoring of innate myeloid immune cells in human blood
Innate myeloid cell (IMC) populations form an essential part of innate immunity. Flow cytometric (FCM) monitoring of IMCs in peripheral blood (PB) has great clinical potential for disease monitoring due to their role in maintenance of tissue homeostasis and ability to sense micro-environmental changes, such as inflammatory processes and tissue damage. However, the lack of standardized and validated approaches has hampered broad clinical implementation. For accurate identification and separation of IMC populations, 62 antibodies against 44 different proteins were evaluated. In multiple rounds of EuroFlow-based design-testing-evaluation-redesign, finally 16 antibodies were selected for their non-redundancy and separation power. Accordingly, two antibody combinations were designed for fast, sensitive, and reproducible FCM monitoring of IMC populations in PB in clinical settings (11-color; 13 antibodies) and translational research (14-color; 16 antibodies). Performance of pre-analytical and analytical variables among different instruments, together with optimized post-analytical data analysis and reference values were assessed. Overall, 265 blood samples were used for design and validation of the antibody combinations and in vitro functional assays, as well as for assessing the impact of sample preparation procedures and conditions. The two (11- and 14-color) antibody combinations allowed for robust and sensitive detection of 19 and 23 IMC populations, respectively. Highly reproducible identification and enumeration of IMC populations was achieved, independently of anticoagulant, type of FCM instrument and center, particularly when database/software-guided automated (vs. manual "expert-based") gating was used. Whereas no significant changes were observed in identification of IMC populations for up to 24h delayed sample processing, a significant impact was observed in their absolute counts after >12h delay. Therefore, accurate identification and quantitation of IMC populations requires sample processing on the same day. Significantly different counts were observed in PB for multiple IMC populations according to age and sex. Consequently, PB samples from 116 healthy donors (8-69 years) were used for collecting age and sex related reference values for all IMC populations. In summary, the two antibody combinations and FCM approach allow for rapid, standardized, automated and reproducible identification of 19 and 23 IMC populations in PB, suited for monitoring of innate immune responses in clinical and translational research settings
A study of thermal oxidation and plasma-enhanced oxidation/reduction of ALD TiN layers
The applications of TiN films in IC technology (i.e., diffusion barrier, gate material, current conductor, and heater) are based on their high thermodynamic stability, low electrical resistivity, and high mechanical hardness. Sputtered stoichiometric TiN exhibits insignificant oxidation rate at temperatures below 4000 C [1], whereas a non- stoichiometric TiN starts to oxidize even at room temperature [2]. The oxidation behavior of thin TiN layers, realized by ALD technique, is hardly investigated. To further promote the use of ALD TiN in novel electron devices (e.g., 3D low-temperature electronics, TFTs, etc.) and for wafer post-processing, both the stability and evolution of the layer properties at different temperatures, during the device operation or processing in reactive plasmas, must be explored
Aprotinin in orthotopic liver transplantation: Evidence for a prohemostatic, but not a prothrombotic, effect
Aprotinin reduces blood transfusion requirements in
orthotopic liver transplantation (OLT). Concern has been
voiced about the potential risk for thrombotic complications
when aprotinin is used. The aim of this study is to
evaluate the effects of aprotinin on the two components of
the hemostatic system (coagulation and fibrinolysis) in
patients undergoing OLT. As part of a larger, randomized,
double-blind, placebo-controlled study, we compared
coagulation (fibrinogen level, activated partial thromboplastin
time [aPTT], prothrombin time, and platelet
count) and fibrinolytic variables (tissue-type plasminogen
activator [tPA] antigen and activity, plasminogen activator
inhibitor activity, and D-dimer), as well as thromboelastography
(reaction time [r], clot formation time,
and maximum amplitude) in 27 patients administered
either high-dose aprotinin (2 ! 106 kallikrein inhibitor
units [KIU] at induction, continuous infusion of 1 ! 106
KIU/h, and 1 ! 106 KIU before reperfusion; n " 10),
regular-dose aprotinin (2 ! 106 KIU at induction and
continuous infusion of 0.5 ! 106 KIU/h; n " 8), or
placebo (n " 9) during OLT. Blood samples were drawn
at seven standardized intraoperative times. Baseline characteristics
were similar for the three groups. During the
anhepatic and postreperfusion periods, fibrinolytic activity
(plasma D-dimer and tPA antigen levels) was significantly
lower in aprotinin-treated patients compared with
the placebo group. Interestingly, coagulation times (aPTT
and r) were significantly more prolonged in aprotinintreated
patients than the placebo group. No difference was
seen in the incidence of perioperative thrombotic complications
in the entire study population (n " 137). Aprotinin
has an anticoagulant rather than a procoagulant
effect. Its blood-sparing (prohemostatic) effect appears
to be the overall result of a strong antifibrinolytic and a
weaker anticoagulant effect. These findings argue against
a prothrombotic effect of aprotinin in patients undergoing
OLT. (Liver Transpl 2001;7:896-903.